Pharmacotherapy of relapsed metastatic testicular cancer

Bibliography

• Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990;8:1777-81
   PubMed Web of Science ®Google Scholar
• Nichols CR, Roth BJ, Loehrer PJ, et al. Salvage chemotherapy for recurrent germ cell cancer. Semin Oncol 1994;5(Suppl 12):102-8
   PubMed Web of Science ®Google Scholar
• Rick O, Siegert W and Beyer J. Chemotherapy in patients with metastatic or relapsed germ-cell tumours. Cancer Treat Rev 2001;27:283-8
   PubMed Web of Science ®Google Scholar
• Beyer J, Kramar A, Mandanas R, et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 1996;14:2638-45
   PubMed Web of Science ®Google Scholar
• Nichols CR. Treatment of recurrent germ cell tumors. Semin Surg Oncol 1999;17:268-74
   PubMedGoogle Scholar
• Porcu P, Bhatia S, Einhorn LH. Results of treatment after relapse from high-dose chemotherapy in germ cell tumors. J Clin Oncol 2000;18:1181-6
   PubMed Web of Science ®Google Scholar
• Loehrer PJS, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998;16:2500-4
   PubMed Web of Science ®Google Scholar
• Loehrer P-JS, Einhorn LH, Williams SD. VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol 1986;4:528-36
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Sheinfeld J, Mazumdar M, et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 2000;18:2413-8
   PubMed Web of Science ®Google Scholar
• Miller KD, Loehrer PJ, Gonin R, et al. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol 1997;15:1427-31
   PubMed Web of Science ®Google Scholar
• Vuky J, Tickoo SK, Sheinfeld J, et al. Salvage chemotherapy for patients with advanced pure seminoma. J Clin Oncol 2002;20:297-301
   PubMed Web of Science ®Google Scholar
• Mead GM, Cullen MH, Huddart R, et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer 2005;93:178-84
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Sheinfeld J, et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 2000;18:1173-80
   PubMed Web of Science ®Google Scholar
• Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007;357:340-8
   PubMed Web of Science ®Google Scholar
• Mead G, Group ftIGCCC. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997;15:594-603
   PubMed Web of Science ®Google Scholar
• McCaffrey JA, Mazumdar M, Bajorin DF, et al. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol 1997;15:2559-63
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Geller NL, Tan CC, et al. Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979 – 1989). Cancer 1991;67:1305-10
   PubMed Web of Science ®Google Scholar
• Baniel J, Foster RS, Gonin R, et al. Late relapse of testicular cancer. J Clin Oncol 1995;13:1170-6
   PubMed Web of Science ®Google Scholar
• Gerl A, Clemm C, Schmeller N, et al. Prognosis after salvage treatment for unselected male patients with germ cell tumours. Br J Cancer 1995;72:1026-32
   PubMed Web of Science ®Google Scholar
• Fossa SD, Stenning SP, Gerl A, et al. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 1999;80:1392-9
   PubMed Web of Science ®Google Scholar
• Nichols CR, Tricot G, Williams SD, et al. Dose-intensive chemotherapy in refractory germ cell cancer – a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989;7:932-9
   PubMed Web of Science ®Google Scholar
• Lorch A, Kollmannsberger C, Hartmann JT, et al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol 2007;25:2778-84
   PubMed Web of Science ®Google Scholar
• Kondagunta GV, Bacik J, Sheinfeld J, et al. Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol 2007;25:85-90
   PubMed Web of Science ®Google Scholar
• Pico JL, Rosti G, Kramar A, et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 2005;16:1152-9
   PubMed Web of Science ®Google Scholar
• Beyer J, Stenning S, Gerl A, et al. High-dose versus conventional-dose chemotherapy as first-line treatment in patients with non-seminomatous germ-cell tumors: a matched pair analysis. Ann Oncol 2002;13:599-605
   PubMed Web of Science ®Google Scholar
• Miller JC, Einhorn LH. Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol 1990;17:36-9
   PubMed Web of Science ®Google Scholar
• Williams SD, Birch R, Gams R, et al. Phase II trial of mitoxantrone in refractory germ cell tumors: a trial of the Southeastern Cancer Study Group. Cancer Treat Rep 1985;69:1455-6
   PubMedGoogle Scholar
• Harstrick A, Schmoll HJ, Wilke H, et al. High dose epirubicin in refractory or relapsed non-seminomatous testicular cancer: a phase II study. Ann Oncol 1990;1:375-6
   PubMed Web of Science ®Google Scholar
• Stoter G, Akdas A, Fossa SD, et al. High-dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer: a phase II study. Ann Oncol 1992;3:577-8
   PubMed Web of Science ®Google Scholar
• Hoskins P, Coppin CM, Murray N. Mitomycin is active against refractory germ-cell tumors. A phase II study. Am J Clin Oncol 1990;13:35-8
   PubMed Web of Science ®Google Scholar
• Strumberg D, Harstrick A, Doll K, et al. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 1996;7:415-21
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Gerl A, Schleucher N, et al. Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer. Anticancer Drugs 2000;11:535-9
   PubMed Web of Science ®Google Scholar
• Berney DM, Shamash J, Gaffney J, et al. DNA topoisomerase I and II expression in drug resistant germ cell tumours. Br J Cancer 2002;87:624-9
   PubMed Web of Science ®Google Scholar
• Puc HS, Bajorin D, Bosl GJ, et al. Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. Invest New Drugs 1995;13:163-5
   PubMed Web of Science ®Google Scholar
• Miki T, Sawada M, Nonomura N, et al. Antitumor effect of CPT-11, a camptothecin derivative, on human testicular tumor xenografts in nude mice. Eur Urol 1997;31:92-6
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Rick O, Klaproth H, et al. Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. Br J Cancer 2002;87:729-32
   PubMed Web of Science ®Google Scholar
• Pera MF, Koberle B, Masters JR. Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolamide. Br J Cancer 1995;71:904-6
   PubMed Web of Science ®Google Scholar
• Kondagunta V, Bacik J, Schwartz L, et al. Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors. Investigational New Drugs 2004;22:177-9
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bajorin D, Schwartz LH, et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994;12:2277-83
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Beyer J, Metzner B, et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 1996;7:31-4
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Nichols C, Bokemeyer C. Recent advances in management of patients with platinum-refractory testicular germ cell tumors. Cancer 2006;106:1217-26
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Hartmann JT, Kuczyk MA, et al. The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors. World J Urol 1996;14:354-9
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Gerl A, Schöffski P, et al. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 1999;17:512-6
   PubMed Web of Science ®Google Scholar
• Einhorn LH, Stender MJ, Williams SD. Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol 1999;17:509-11
   PubMed Web of Science ®Google Scholar
• Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996;56:4881-6
   PubMed Web of Science ®Google Scholar
• Dunn TA, Schmoll HJ, Grünwald V, et al. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell lines. Invest New Drugs 1997;15:109-14
   PubMed Web of Science ®Google Scholar
• Hinton S, Catalano PJ, Einhorn L, et al. Phase II trial of paclitaxel and gemcitabine in refractory germ cell tumors. J Clin Oncol 2001;20:1859-63
   Web of Science ®Google Scholar
• Einhorn LH, Brames MJ, Juliar B, et al. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol 2007;25:513-6
   PubMed Web of Science ®Google Scholar
• Faivre S, Raymond E, Woynarowski JM, et al. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999;44:117-23
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Beyer J, Liersch R, et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2004;22:108-14
   PubMed Web of Science ®Google Scholar
• Pectasides D, Pectasides M, Farmakis D, et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol 2004;15:493-7
   PubMed Web of Science ®Google Scholar
• De Giorgi U, Rosti G, Papiani G, et al. Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with cisplatin-refractory germ cell tumor: preliminary experience. Am J Clin Oncol 2004;27:457-60
   PubMed Web of Science ®Google Scholar
• Theodore C, Flechon A, Fizazi K, et al. A phase II multicentre study of oxaliplatin (Ox) in combination with paclitaxel (Px) in patients (pts) who failed cisplatin (CDDP) based chemotherapy (CT) for germ cell tumors (GCT) [abstract 4534]. Proc Am Soc Clin Oncol 2004;23:389
   Google Scholar
• Miki T, Mizutani Y, Nonomura N, et al. Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors. Cancer 2002;95:1879-85
   PubMed Web of Science ®Google Scholar
• Kano Y, Suzuki K, Akutsu M, et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 1992;50:604-10
   PubMed Web of Science ®Google Scholar
• Zeghari-Squalli N, Raymond E, Cvitkovic E, et al. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res 1999;5:1189-96
   PubMed Web of Science ®Google Scholar
• Shamash J, Powles T, Mutsvangwa K, et al. A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours. Annals of oncology 2007;18:925-30
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Oechsle K, Honecker F, et al. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol 2008;19:448-53
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Dmitrovsky E, Miller WHJ, et al. Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial. Cancer 1993;72:3313-7
   PubMed Web of Science ®Google Scholar
• Moasser MM, Motzer RJ, Khoo KS, et al. All-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial. Cancer 1995;76:680-6
   PubMed Web of Science ®Google Scholar
• Fukuda S, Shirahama T, Imazono Y, et al. Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease. Cancer 1999;85:1323-30
   PubMed Web of Science ®Google Scholar
• Viglietto G, Romano A, Maglione D, et al. Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor. Oncogene 1996;13:577-87
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Mayer F, Pressler H, et al. Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer. Cancer 2002;95:301-8
   PubMed Web of Science ®Google Scholar
• Kemmer K, Corless CL, Fletcher JA, et al. KIT mutations are common in testicular seminomas. Am J Pathol 2004;164:305-13
   PubMed Web of Science ®Google Scholar
• Tian Q, Frierson HF, Krystal GW, et al. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 1999;154:1643-7
   PubMed Web of Science ®Google Scholar
• Madani A, Kemmer K, Sweeney C, et al. Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. Ann Oncol 2003;14:873-80
   PubMed Web of Science ®Google Scholar
• Bajorin DF, Nichols CR, Margolin KA, et al. Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell tumors (GCT) patients (PTS): a cooperative group trial by Memorial Sloan-Kettering Cancer Center, ECOG, SWOG, and CALGB [abstract 4510]. Proc Am Soc Clin Oncol 2006;24
   Google Scholar
• Beer TM, Tangen CM, Nichols CR, et al. Southwest Oncology Group Phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer 2006;106:2624-9
   PubMed Web of Science ®Google Scholar
• Moroni M, Veronese S, Schiavo R, et al. Epidermal growth factor receptor expression and activation in nonseminomatous germ cell tumors. Clin Cancer Res 2001;7:2770-5
   PubMed Web of Science ®Google Scholar
• Soule S, Baldridge L, Kirkpatrick K, et al. HER-2/neu expression in germ cell tumours. J Clin Pathol 2002;55:656-8
   PubMed Web of Science ®Google Scholar
• Hartmann JT, Schmoll HJ, Kuczyk MA, et al. Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. Ann Oncol 1997;8:531-8
   PubMed Web of Science ®Google Scholar
• Hendry WF, Norman AR, Dearnaley DP, et al. Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer 2002;94:1668-76
   PubMed Web of Science ®Google Scholar
• Rick O, Bokemeyer C, Weinknecht S, et al. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. J Clin Oncol 2004;22:3713-9
   PubMed Web of Science ®Google Scholar
• Sonneveld DJ, Sleijfer DT, Koops HS, et al. Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors: a plea for an aggressive surgical approach. Cancer 1998;82:1343-51
   PubMed Web of Science ®Google Scholar
• Stenning SP, Parkinson MC, Fisher C, et al. Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party. Cancer 1998;83:1409-19
   PubMed Web of Science ®Google Scholar
• Murphy BR, Breeden ES, Donohue JP, et al. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 1993;11:324-9
   PubMed Web of Science ®Google Scholar
• Eastham JA, Wilson TG, Russell C, et al. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. Urology 1994;43:74-80
   PubMed Web of Science ®Google Scholar
• Coogan CL, Foster RS, Rowland RG, et al. Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone. Urology 1997;50:957-62
   PubMed Web of Science ®Google Scholar
• Albers P, Ganz A, Hannig E, et al. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol 2000;164:381-4
   PubMed Web of Science ®Google Scholar
• Foster R, Beck S, Bihrle R, et al. Results of post chemotherapy retroperitoneal lymph node dissection for patients with persistently elevated tumor markers [abstract 713]. Proc Am Soc Clin Oncol 2001;20:179a
   Web of Science ®Google Scholar
• Beck SD, Foster RS, Bihrle R, et al. Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer. Urol Oncol 2005;23:423-30
   PubMed Web of Science ®Google Scholar
• George DW, Foster RS, Hromas RA, et al. Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol 2003;21:113-22
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Martin JM, Fossa SD. Late relapses of germ cell malignancies: incidence, management, and prognosis. J Clin Oncol 2006;24:5503-11
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Souchon R, Krege S, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004;15:1377-99
   PubMed Web of Science ®Google Scholar
• Sonneveld DJ, Hoekstra HJ, Van-der GW, et al. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer 2001;91:1304-15
   PubMed Web of Science ®Google Scholar
• Nichols CR, Maziarz R. High-dose chemotherapy-treatment results in the USA. Int J Cancer 1999;83:841-3
   PubMed Web of Science ®Google Scholar
• Farmakis D, Pectasides D, Pectasides M, et al. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor (G-CSF) as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor (GCT) patients: a phase II study [abstract 4545]. Proc Am Soc Clin Oncol 2004;23:389
   Google Scholar
• Bosl GJ, Yagoda A, Golbey RB, et al. Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumors. Am J Med 1985;78:423-8
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Williams SD, Einhorn LH, et al. Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trial. J Clin Oncol 1985;3:666-71
   PubMed Web of Science ®Google Scholar
• Pizzocaro G, Pasi M, Salvioni R, et al. Cisplatin and etoposide salvage therapy and resection of the residual tumor in pretreated germ cell testicular cancer. Cancer 1985;56:2399-403
   PubMed Web of Science ®Google Scholar
• Loehrer PJ, Lauer R, Roth BJ, et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 1988;109:540-6
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Cooper K, Geller NL, et al. The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer 1990;66:2476-81
   PubMed Web of Science ®Google Scholar
• Harstrick A, Schmoll HJ, Wilke H, et al. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J Clin Oncol 1991;9:1549-55
   PubMed Web of Science ®Google Scholar
• Josefsen D, Ous S, Hoie J, et al. Salvage treatment in male patients with germ cell tumours. Br J Cancer 1993;67:568-72
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Holden L, Newlands ES, et al. The long-term outcome of patients who relapse after chemotherapy for non-seminomatous germ cell tumours. Br J Urol 1994;74:225-30
   PubMedGoogle Scholar
• Farhat F, Culine S, Theodore C, et al. Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: the Institut Gustave Roussy experience. Cancer 1996;77:1193-7
   PubMed Web of Science ®Google Scholar
• Shamash J, Oliver RT, Ong J, et al. Sixty percent salvage rate for germ-cell tumours using sequential m-BOP, surgery and ifosfamide-based chemotherapy. Ann Oncol 1999;10:685-92
   PubMed Web of Science ®Google Scholar
• Kondagunta VG, Bacik J, Bajorin D, et al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol 2005;23:9290-4
   PubMed Web of Science ®Google Scholar
• Siegert W, Beyer J, Strohscheer I, et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. J Clin Oncol 1994;12:1223-31
   PubMed Web of Science ®Google Scholar
• Rodenhuis S, de Wit R, de Mulder PH, et al. A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission. Ann Oncol 1999;10:1467-73
   PubMed Web of Science ®Google Scholar
• Rick O, Bokemeyer C, Beyer J, et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stell cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 2001;19:81-8
   PubMed Web of Science ®Google Scholar
• Choo R, Thomas G, Woo T, et al. Long-term outcome of postorchiectomy surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys 2005;61:736-40
   PubMed Web of Science ®Google Scholar
• Williams SD, Duncan P, Einhorn LH. Phase II study of AMSA in refractory testicular cancer. Cancer Treat Rep 1983;67:309-10
   PubMedGoogle Scholar
• Drasga RE, Williams S, Einhorn LH, et al. Phase II evaluation of iproplatin in refractory germ cell tumors: a Southeastern Cancer Study Group trial. Cancer Treat Rep 1987;71:863-4
   PubMedGoogle Scholar
• Murphy B, Motzer RJ, Bosl GJ. Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT. Invest New Drugs 1992;10:327-30
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Droz JP, Hanauske A, et al. Treatment of relapsed nonseminomatous germ cell tumors with vinorelbine: a trial of the phase I/II study group of the Association of Medical Oncology of the German Cancer Society. Onkologie 1993;16:29-31
   Web of Science ®Google Scholar
• Oechsle K, Honecker F, Kollmannsberger C, et al. An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors. Anticancer Drugs 2007;18:273-6
   PubMed Web of Science ®Google Scholar
• Rick O, Braun T, Siegert W, et al. Activity of thalidomide in patients with platinum-refractory germ-cell tumours. Eur J Cancer 2006;42:1775-9
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Preßler H, Kanz L, et al. Cisplatin-refractory, HER2/neu expressing germ cell cancer: induction of remission by the monoclonal antibody Trastuzumab. Ann Oncol 1999;10:1393-5
   PubMed Web of Science ®Google Scholar
• Voigt W, Kegel T, Maher G, et al. Bevacizumab plus high-dose ifosfamide, etoposide and carboplatin (HD-ICE) as third-line salvage chemotherapy induced an unexpected dramatic response in highly platinum refractory germ-cell cancer. Ann Oncol 2006;17:531-3
   PubMed Web of Science ®Google Scholar
• Mego M, Reckova M, Sycova-Mila Z, et al. Bevacizumab in a growing teratoma syndrome. Case report. Ann Oncol 2007;18:962-3
   PubMed Web of Science ®Google Scholar
• Pedersini R, Vattemi E, Mazzoleni G, et al. Complete response after treatment with imatinib in pretreated disseminated testicular seminoma with overexpression of c-KIT. Lancet Oncol 2007;8:1039-40
   PubMed Web of Science ®Google Scholar